Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Pulmonology
  • Pulmonology News
  • 24-week regimen of...

24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin bests standard-care treatment for rifampin-resistant tuberculosis

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-12-22T08:00:00+05:30  |  Updated On 22 Dec 2022 8:00 AM IST
24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin bests standard-care treatment for rifampin-resistant tuberculosis
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Standard-care treatment was similarly efficacious when patients could receive it without adverse effects, according to findings from a two-stage, phase 2–3 clinical trial.

Delhi: A 24-week all-oral regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin was shown to be non-inferior to the accepted standard-care treatment in patients with rifampin-resistant pulmonary tuberculosis and had a better safety profile in a recent study.

The study findings were featured in the New England Journal of Medicine.

Worldwide in 2019, about 465,000 patients were affected by rifampin-resistant tuberculosis. 59% of the patients with rifampin-resistant tuberculosis who began treatment initiation in 2018 have had successful outcomes, and there was not much improvement in this incidence in the past five years.

The main challenges include social disruption, adverse events, and cost. These shortcomings led to the need for more effective, shorter treatments with a more acceptable side-effect profile than the current regimens. In programmatic care settings, the recommended treatment duration is 9 to 20 months and involves up to 20 tablets per day.

Against the above background, Bern-Thomas Nyang'wa and colleagues aimed to examine the safety and efficacy of 24-week, all-oral regimens for treating rifampin-resistant tuberculosis in a two-stage, phase 2–3 clinical trial, TB-PRACTECAL (Pragmatic Clinical Trial for a more Effective, Concise and Less Toxic Regimen).

The authors enrolled patients in Uzbekistan, South Africa, and Belarus who were 15 years of age and above and had rifampin-resistant pulmonary tuberculosis. In trial stage 2, a comparison was made between a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) and a 9-to-20-month standard-care regimen. Unfavourable status (primary outcome) was described as a composite of treatment failure, death, loss to follow-up, treatment discontinuation, or recurrent tuberculosis at 72 weeks after randomization. The noninferiority margin was 12 percentage points.

The study led to the following findings:

  • Recruitment was terminated early. Of 301 patients in stage 2 of the trial, 145, 128, and 90 were evaluable in the intention-to-treat, modified intention-to-treat, and per-protocol populations, respectively.
  • In the modified intention-to-treat analysis, 11% of the patients in the BPaLM group and 48% of those in the standard care group had a primary-outcome event (risk difference, −37 percentage points).
  • In the per-protocol analysis, 4% of the patients in the BPaLM group and 12% of those in the standard care group had a primary-outcome event (risk difference, −9 percentage points).
  • In the as-treated population, the incidence of grade 3 or higher adverse events or serious adverse events was lower in the BPaLM group than in the standard care group (19% vs. 59%).

Findings indicate that BPaLM was both non-inferior and superior to the accepted standard care concerning the primary composite outcome; 89% and 52% of the patients, respectively, had favourable results.

Also, the percentage of patients with favourable outcomes in the BPaL group (77%) and the BPaLC group (81%) was more significant than in the standard care group. The difference was driven mainly by early treatment discontinuation due to adverse events in the standard-care group. The difference between the standard-care and investigational groups was less noticeable in the per-protocol analysis, where early discontinuations were excluded.

"These findings suggest that the standard-care treatment was similarly efficacious when patients could receive it without adverse effects," the authors concluded.

Reference:

The study "24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis" was published in the New England Journal of Medicine.

DOI: 10.1056/NEJMoa2117166


New England Journal of MedicineRifampin-Resistant Tuberculosisbedaquilinepretomanidlinezolidmoxifloxacin
Source : New England Journal of Medicine
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    High Blood Pressure in Children Tied to Mothers Pregnancy Health: NIH Study Finds

    High Blood Pressure in Children Tied to Mother's Pregnancy Health: NIH Study Finds

    View All

    Health News Today

    Health Bulletin 10/ May/ 2025

    Health Bulletin 10/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok